Abstract | BACKGROUND: METHODS: We examined the incidence, clinical course, and outcomes of patients with APL treated on Intergroup Protocol 0129 (I0129) who developed PTC. This trial evaluated the role of ATRA alone during induction and/or as maintenance therapy. RESULTS: Of the patients on trial, 240 received ATRA during induction, maintenance, or both; 8 had a clinical suspicion for PTC. Upon review of individual cases, this was felt to be "probable" in 4 patients, "possible" in 1 and "unlikely" in 3 due to lack of diagnostic criteria or presence of a more likely alternate diagnosis. CONCLUSIONS: "Probable" PTC occurred in 1.7% of patients who received ATRA during induction and/or maintenance therapy. In agreement with previous reports, the incidence of PTC in APL patients receiving ATRA was higher in the pediatric population. Here, we discuss the method for diagnosing PTC in the setting of ATRA therapy and management strategies.
|
Authors | Catherine C Coombs, Lisa M DeAngelis, James H Feusner, Jacob M Rowe, Martin S Tallman |
Journal | Clinical lymphoma, myeloma & leukemia
(Clin Lymphoma Myeloma Leuk)
Vol. 16
Issue 3
Pg. 146-51
(Mar 2016)
ISSN: 2152-2669 [Electronic] United States |
PMID | 26724834
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2016 Elsevier Inc. All rights reserved. |
Chemical References |
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Female
- Humans
- Incidence
- Induction Chemotherapy
- Leukemia, Promyelocytic, Acute
(complications, drug therapy)
- Maintenance Chemotherapy
- Male
- Pseudotumor Cerebri
(diagnosis, epidemiology, etiology, therapy)
- Randomized Controlled Trials as Topic
- Treatment Outcome
- Tretinoin
(adverse effects, therapeutic use)
- Young Adult
|